Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis

Inclusion Criteria: * Age≥18 * Histologic confirmation of gastric adenocarcinoma * Positive peritoneal cytology or histological proven PC * Absence of other distant metastases except peritoneum and lymph node(s) * Adequate bone marrow and organ functions as defined below: * Leucocyte ≥3.00 x 109/L * Absolute neutrophil counts ≥ 1.50 x 109/L * Platelet ≥ 100 x 109/L * Total bilirubin ≤2 x ULN * AST/ALT ≤2.5 x ULN * Creatinine clearance ≥60ml/min * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Subjects of child-bearing potential must agree to contraception from screening to 6 months after completion of treatment * Provision of written informed consent Exclusion Criteria: * Any prior anti-cancer therapy for gastric cancer * Previous exposure to taxane, fluoropyrimidine or platinum chemotherapy * Previous radiotherapy to abdomen or pelvic region * Known hypersensitivity to study medication * Known dihydropyrimidine dehydrogenase (DPD) deficiency * Any prior or synchronous malignancy, except, * Malignancy treated with curative intent and with no evidence of disease for ≥5 years prior to enrollment and considered to be at low risk for recurrence by the treating physician * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Subject is pregnant or breast feeding * Any serious concomitant illness